GGT/ALT ratio is related to serum markers of fibrosis and predict sustained response to interferon (IFN) plus ribavirin (RBV) in non-responder/relapser patients with chronic hepatitis (CHC)

2001 ◽  
Vol 34 (0) ◽  
pp. 125-126
Author(s):  
J Moreno-Monteagudo
Keyword(s):  
Chronic Hepatitis ◽  
Serum Markers ◽  
Sustained Response

Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B

2012 ◽  
Vol 43 (6) ◽  
pp. 596-604 ◽  
Author(s):  
Kenji Ikeda ◽  
Namiki Izumi ◽  
Eiji Tanaka ◽  
Hiroshi Yotsuyanagi ◽  
Yoshihisa Takahashi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Serum Markers ◽  
Fibrosis Score

Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin

2005 ◽  
Vol 25 (1) ◽  
pp. 91-95 ◽  
Author(s):  
J. F. Gallegos-Orozco ◽  
A. Loaeza-del Castillo ◽  
A. P. Fuentes ◽  
M. García-Sandoval ◽  
L. Soto ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Sustained Response ◽  
Peginterferon Α

scholarly journals Chronic hepatitis C virus infections in Brazilian patients: association with genotypes, clinical parameters and response to long term alpha interferon therapy

1999 ◽  
Vol 41 (3) ◽  
pp. 183-189 ◽  
Author(s):  
Leda BASSIT ◽  
Luiz C. DA SILVA ◽  
Gabriela RIBEIRO-DOS-SANTOS ◽  
Geert MAERTENS ◽  
Flair J. CARRILHO ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hcv Infection ◽  
Sustained Response ◽  
Response To Treatment ◽  
Recombinant Interferon ◽  
Genotype 2

The present study assessed the clinical significance of hepatitis C virus (HCV) genotypes and their influence on response to long term recombinant-interferon-alpha (r-IFN-<FONT FACE="Symbol">a</FONT>) therapy in Brazilian patients. One hundred and thirty samples from patients previously genotyped for the HCV and with histologically confirmed chronic hepatitis C (CH-C) were evaluated for clinical and epidemiological parameters (sex, age, time of HCV infection and transmission routes). No difference in disease activity, sex, age or mode and time of transmission were seen among patients infected with HCV types 1, 2 or 3. One hundred and thirteen of them were treated with 3 million units of r-IFN-<FONT FACE="Symbol">a</FONT>, 3 times a week for 12 months. Initial response (IR) was significantly better in patients with genotype 2 (100%) and 3 (46%) infections than in patients with genotype 1 (29%) (p < 0.005). Among subtypes, difference in IR was observed between 1b and 2 (p < 0.005), and between 1b and 3a (p < 0.05). Sustained response (SR) was observed in 12% for (sub)type 1a, 13% for 1b, 19% for 3a, and 40% for type 2; significant differences were found between 1b and 2 (p < 0.001), and between 1b and 3a (p < 0.05). Moreover, presence of cirrhosis was significantly associated with non response and response with relapse (p < 0.05). In conclusion, non-1 HCV genotype and lack of histological diagnosis of cirrhosis were the only baseline features associated with sustained response to treatment. These data indicate that HCV genotyping may have prognostic relevance in the responsiveness to r-IFN-<FONT FACE="Symbol">a</FONT> therapy in Brazilian patients with chronic HCV infection, as seen in other reports worldwide.

Sign in / Sign up

Export Citation Format

Share Document